Complete response to adriamycin and ifosfamide in a patient with sarcomatoid renal cell carcinoma.
Sarcomatoid renal cell carcinoma (SRCC) is a heterogeneous disease with generally unreliable response to various therapies in clinical studies. We illustrate a case report in which a woman with metastatic SRCC had a complete and durable response to adriamycin and ifosfamide chemotherapy. We find this to be incongruous with expectations from some recently published data. It underscores the fact that the biology of SRCC needs to be studied in more detail for further subcataloging of the disease into diverse prognostic categories.
Rashid
Mohammad H
MH
Department of Medicine, Division of Hematology/Oncology, Medical University of South Carolina, Charleston, South Carolina, USA.
Welsh
Cynthia T
CT
Bissada
Nabil K
NK
Chaudhary
Uzair B
UB
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000145:classification* / Q000188:drug therapy* / Q000556:secondary; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D007372:Interferons / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D012074:Remission Induction
D004317:Doxorubicin; D007372:Interferons; D007069:Ifosfamide